Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), announced that Phase 3 clinical trials for AMG 162 (hereafter, denosumab), a gene recombinant drug for patients with rheumatoid arthritis, has achieved a major objective.
The study conducted in Japan consisted of randomized, double-blind, placebo-controlled Phase 3 clinical trials in patients with rheumatoid arthritis with disease-modifying anti-rheumatic drugs (DMARDs).
In this study, denosumab showed excellent effects in preventing structural joint damage.
